公开(公告)号：EP1986706A2

公开(公告)日：2008-11-05

申请号：EP07710404.0

申请日：2007-01-30

申请人： Surgica Corporation

发明人： MCNAMARA, Gerald, R. ,  BRANDOM, Donald, K. ,  BALKENHOL, Wayne, J. ,  MATSON, Louis, R.

IPC分类号： A61L24/00 ,  A61L24/06

CPC分类号： A61L24/0036 ,  A61L24/06 ,  A61L2430/36 ,  C08L29/04

摘要： The present invention relates to porous embolization devices, methods of making and using the devices as well as methods and devices to hydrate and deliver embolization particles.

摘要翻译： 本发明涉及多孔栓塞装置，制造和使用该装置的方法以及水合和递送栓塞颗粒的方法和装置。

公开(公告)号：EP1952578A1

公开(公告)日：2008-08-06

申请号：EP06790349.2

申请日：2006-10-10

申请人： Seeker Wireless PTY Limited

发明人： DRANE, Christopher, Ridgway ,  SCOTT, Craig, Andrew ,  MACNAUGHTAN, Malcolm, David ,  BROWN, Stephen

IPC分类号： H04L12/12 ,  H04L12/28 ,  H04Q7/32

CPC分类号： H04W4/02 ,  H04L67/18 ,  H04W8/205 ,  H04W64/00

摘要： A mobile radio communications network is disclosed in which zones may be defined for provision of location based services and applications. Various methods are also disclosed for using the defined zones in different ways for different applications. The methods include associating users with zones, updating users of zones with changes to the zones, controlling zone size and dynamically uploading zone profiles to users based on the user's geographical location.

公开(公告)号：EP1919500A2

公开(公告)日：2008-05-14

申请号：EP06787293.7

申请日：2006-07-12

申请人： Anthrogenesis Corporation

发明人： HARIRI, Robert, J. ,  SMIELL, Janice, M.

IPC分类号： A61K38/39 ,  A61P17/02

CPC分类号： A61L15/40 ,  A61F13/069 ,  A61F15/001 ,  A61F2013/0054 ,  A61F2013/00548 ,  A61F2013/0091 ,  A61F2013/00927 ,  A61K31/728 ,  A61K38/1841 ,  A61K38/1858 ,  A61K38/2292 ,  A61K38/363 ,  A61K38/39 ,  A61K38/4833 ,  A61L15/32 ,  A61L15/325 ,  A61L15/44 ,  A61L26/0033 ,  A61L26/0057 ,  A61L27/3604 ,  A61L27/60 ,  A61L31/005 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2430/34 ,  A61L2430/40 ,  Y10T428/249921 ,  A61K2300/00

摘要： The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.

公开(公告)号：EP1917250A2

公开(公告)日：2008-05-07

申请号：EP06785683.1

申请日：2006-06-26

申请人： Amgen, Inc

发明人： BERGERON, Philippe ,  CHEN, Xiaoqi ,  DU, Xiaohui ,  DEIGNAN, Jeffrey ,  DUQUETTE, Jason, A. ,  GUSTIN, Darin ,  MEDINA, Julio, C. ,  MIHALIC, Jeffrey, T. ,  TONN, George, R.

IPC分类号： C07D233/54

CPC分类号： C07D233/64 ,  C07D235/14 ,  C07D239/26 ,  C07D239/90 ,  C07D401/04 ,  C07D409/12 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

摘要： Compounds, (I) compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides aryl nitrile compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis, type I diabetes, asthma, psoriasis and inflammatory bowel disease. All definitions are as given in claim 1.

摘要翻译： 本文提供了可用于治疗炎症和免疫病症和疾病的化合物，（I）组合物和方法。 特别地，本发明提供了调节趋化因子受体的表达和/或功能的芳基腈化合物。 本发明方法可用于治疗炎症和免疫调节紊乱和疾病，例如多发性硬化，类风湿性关节炎，I型糖尿病，哮喘，牛皮癣和炎性肠病。 所有定义如权利要求1中给出。

公开(公告)号：EP1893175A1

公开(公告)日：2008-03-05

申请号：EP05758570.5

申请日：2005-06-09

申请人： Upm Pharmaceuticals, Inc.

发明人： HOLLENBECK, R., Gary

IPC分类号： A61K9/10 ,  A61K47/36 ,  A61K47/48 ,  A61K31/135

CPC分类号： A61K9/0095 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/135 ,  A61K47/585

摘要： The present invention relates to liquid sustained release suspension dosage forms comprising ionized forms of water-soluble drugs. In particular, the invention encompasses a liquid form controlled release drug composition comprising a dispersed phase comprising an ion-exchange matrix drug complex comprising a pharmaceutically acceptable a ion-exchange matrix and a water-soluble electrolytic drug associated with the ion-exchange matrix, wherein the surface charge of the ion-exchange matrix is opposite that of the electrolytic drug wherein the dispersed phase further comprises a non-electrolytic, soluble component having low molecular weight and a diffusion controlling membrane and a dispersion medium substantially free of diffusible counterions, further comprising an excipient capable of associating with water and impeding water activity such that drug dissolution is inhibited prior to administration. The invention also provides methods for preparing such compositions and methods of treatment.

公开(公告)号：EP1176956B1

公开(公告)日：2008-01-09

申请号：EP00937527.0

申请日：2000-05-05

申请人： ENCYSIVE PHARMACEUTICALS, INC

发明人： BIEDIGER, Ronald, J. ,  CHEN, Qi ,  HOLLAND, George, W. ,  KASSIR, Jamal, M. ,  LI, Wen ,  MARKET, Robert, V. ,  SCOTT, Ian, L. ,  WU, Chengde

IPC分类号： A61K31/215 ,  A61K31/335 ,  A61K31/38 ,  A61K31/4025 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/4523 ,  A61K31/47 ,  A61K31/506 ,  C07C69/66 ,  C07D207/04 ,  C07D207/18 ,  C07D211/68 ,  C07D211/72 ,  C07D213/02 ,  C07D215/00

CPC分类号： C07D213/75 ,  C07D239/47 ,  C07D405/12 ,  C07D409/14

摘要： A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either as above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.

公开(公告)号：EP1873165A1

公开(公告)日：2008-01-02

申请号：EP06013165.3

申请日：2006-06-26

申请人： PLS-Design GmbH

发明人： Blank, Simon ,  Bockisch, Benjamin Dr. ,  Grunwald, Thomas Dr.

IPC分类号： C07K14/435 ,  C12N9/50 ,  C12N15/09 ,  C12Q1/68 ,  G01N33/48

CPC分类号： C07K14/43572 ,  C12N9/6402

摘要： The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen C (Api m 5). The invention further relates to expression vectors, host cells and polypeptides encoded by the nucleic acid, as well as diagnostic and pharmaceutical uses thereof.

摘要翻译： 本发明涉及一种编码能够从与来自SEQ ID NO：2的氨基酸序列具有多于70％同源性的膜翅目昆虫的毒液过敏的受试者的能够结合IgE的多肽的核酸，其是SEQ ID NO： 蜂蜜过敏原C（Api m 5）。 本发明还涉及由核酸编码的表达载体，宿主细胞和多肽，以及其诊断和药物用途。

公开(公告)号：EP1651756A1

公开(公告)日：2006-05-03

申请号：EP04771388.8

申请日：2004-08-02

申请人： Nakamura, Norimasa

发明人： NAKAMURA, Norimasa ,  MATSUDA, Hikaru ,  SAWA, Yoshiki ,  TAKETANI, Satoshi ,  MIYAGAWA, Shigeru ,  YOSHIKAWA, Hideki ,  ANDO, Wataru

IPC分类号： C12N5/06

CPC分类号： A61L27/3612 ,  A61K35/12 ,  A61L27/24 ,  A61L27/3633 ,  A61L27/3817 ,  A61L27/3852 ,  A61L27/3895 ,  A61L27/50 ,  A61L2430/06 ,  C07K14/47 ,  C12N5/0654 ,  C12N5/0655 ,  C12N2500/25 ,  C12N2500/38 ,  C12N2501/135 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/20 ,  C12N2501/33 ,  C12N2501/39 ,  C12N2501/999 ,  C12N2502/1311 ,  C12N2506/1384

摘要： The present invention can be used for actual implantation surgery without a scaffold. The present invention provides a synthetic tissue or complex which can be produced by culture and has a high level of differentiation ability. The present invention also provides a therapy and medicament for repairing and/or regenerating tissue using replacement and covering. By culturing cells under specific culture conditions such that medium contains an extracellular matrix synthesis promoting agent, the cells are organized and are easily detached from a culture dish. The present invention was achieved by finding such a phenomenon. In addition, the self contraction of the tissue can be regulated by culturing the tissue in a suspended manner. Therefore, it is possible to regulate the three-dimensional shape of the tissue. The present invention also provides a method for producing an implantable synthetic tissue which does not require a plurality of monolayer cell sheets assembled to form a three-dimensionally structured synthetic tissue. The present invention is characterized by richness in adhesion molecules, nonnecessity of additional fixation at an implantation site, and good biological integration.

公开(公告)号：EP1575658A2

公开(公告)日：2005-09-21

申请号：EP03726286.2

申请日：2003-04-15

申请人： The Regents of the University of California

发明人： ZHOU, Qun-Yong ,  BULLOCK, Clayton, M.

IPC分类号： A61N1/00

CPC分类号： C07K14/47 ,  C07K14/705 ,  G01N33/566 ,  G01N2333/705 ,  G01N2500/04

摘要： The invention provides a method for screening for a compound for modulating circadian rhythm. The method involves (a) providing a compound that is a Prokineticin 2 (PK2) receptor antagonist or agonist; and (b) determining the ability of the compound to modulate one or more indicia of circadian rhythm function, wherein a compound that modulates one or more indicia of circadian rhythm function is identified as a compound for modulating circadian rhythm. The invention also provides a mouse PK2 receptor nucleic acid, polypeptide and related compositions. Further provided is a method for modulating circadian rhythm of an animal, which involves administering an effective amount of a PK2 receptor antagonist or agonist to an animal. Also provided is an isolated nucleic acid comprising a PK2 gene promoter operatively linked to a heterologous nucleotide sequence.

公开(公告)号：EP1514107A2

公开(公告)日：2005-03-16

申请号：EP03756393.9

申请日：2003-06-03

申请人： The Institute for Systems Biology

发明人： AEBERSOLD, Rudolf, H. ,  ZHANG, Hui

IPC分类号： G01N33/53 ,  G01N33/543 ,  G01N33/551 ,  G01N33/48 ,  G01N24/00 ,  G01N1/00 ,  C12N1/00

CPC分类号： G01N33/6848 ,  C12Q1/34 ,  C12Q1/37 ,  G01N33/68 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6851 ,  G01N2400/00 ,  G01N2458/15 ,  Y10T436/24 ,  Y10T436/25125

摘要： The invention provides a method for identifying and quantifying polyglycopeptides in a sample. The method can include the steps of immobilizing glycopolypeptides to a solid support; cleaving the immobilized glycopolypeptides, thereby releasing non-glycosylated peptides and retaining immobilized glycopeptides; releasing the glycopeptides from the solid support; and analyzing the released glycopeptides. The method can further include the step of identifying one or more glycopeptides, for example, using mass spectrometry.